Blossomhill Therapeutics, Inc. · NASDAQ:BLSM
Blossomhill Therapeutics — WCLC 2026
8 slides from Blossomhill Therapeutics's conference presentation, Sep 14, 2026
Slide 1: Anti-tumor activity of BH-30643, a novel macrocyclic EGFR TKI
MO12.02 ANTI-TUMOR ACTIVITY OF BH-30643, A NOVEL MACROCYCLIC EGFR TKI, IN PATIENTS WITH SECONDARY EGFR RESISTANCE MUTATIONS Presenter: Dr. Hidehito Horinouchi National Cancer Center Hospital, Tokyo, Japan Hidehito Horinouchi, Molly Li, Divya Gupta, Hiroki Izumi, Misako Nagasaka, Alexander Spira, Jon
Slide 2: Disclosures
Disclosures I have the following financial relationships to disclose: • Consulting / advisory fees: AstraZeneca, Taiho, Chugai, MSD, Abbvie, Kyowa-Kirin, BMS, Ono, Novartis • Research funding to institution: MSD, Daiichi-Sankyo, Abbvie, Chugai/Roche, AstraZeneca, Ono, BMS, Natera, BlossomHill Therap
Slide 3: Background: Targeting C797S+ resistance
Background: Targeting C797S+ resistance EGFR C797S+ resistance BH-30643 is a macrocyclic, mutant selective to 3rd-gen EGFR TKI OMNI-EGFR TKI • Following progression on 3rd-gen EGFR TKIs, • While macrocyclic ALK & ROS1 TKIs are used widely, no subsequent therapy options are limited for macrocyclic EG
Slide 4: SOLARA: Global Phase 1/2 trial of BH-30643
SOLARA: Global Phase 1/2 trial of BH-30643 • Phase 1 program spans more than 40 sites across 10 countries in North America & APAC1 • Expansion enrollment includes patients with EGFR C797S resistance after prior TKI Study design2 C797S target population (Part 1 and Part 2)3 N=40 Age (years), median (
Slide 5: SOLARA: Efficacy in EGFR C797S+ resistance
SOLARA: Efficacy in EGFR C797S+ resistance • Responses in 18/40 (45% ORR, 95% CI 29%-62%)1 in target population; disease control rate (DCR) of 88% (35/40) • At median follow up of 6.9 months, 25 patients (63%) are still on therapy 45% ORR, 88% DCR 1Responses include confirmed [cPR] or unconfirmed on
Slide 6: SOLARA: Safety experience in expansion dose levels
SOLARA: Safety experience in expansion dose levels Treatment-related adverse events (TRAE) • Dose reduction (9%) and treatment discontinuation in ≥ 10% patients1 (3%) due to TRAE are uncommon Preferred Term, 40 mg, 50 mg, 60 mg BID • EGFR-wildtype associated TRAEs are mostly Grade 1 N=174 N (%) All
Slide 7: Summary & Next Steps
Summary & Next Steps SOLARA enrollment ongoing in North America & APAC • BH-30643 demonstrated a 45% ORR in patients with EGFR C797S-positive resistance to prior TKI, with or without concurrent T790M o Fast Track Designation granted by US FDA for C797S-positive NSCLC after prior 3rd-gen TKI • Safety
Slide 8: Acknowledgements
Acknowledgements: Study sites: USA: SCRI, MDACC, UCSD, UC Davis, NEXT Virginia, UCI, NWM, • The authors thank the SOLARA FCS, SKCC, Moffitt, Henry Ford, Mayo Sites, Fred Hutch, DFCI, MGH, Georgetown, BIDMC, Stanford, Yale, MSKCC, patients and their families, as NYU, Duke, Emory, Cedars-Sinai, UChica